Adcendo to Participate in Expert ADC Panel Debate at BIO-Europe 2024

Copenhagen, Denmark, October 29th, 2024 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of first-in-class ADCs for the treatment of cancers with a high unmet medical need, today announces that its CEO, Michael Pehl will join fellow antibody-drug-conjugate (ADC) industry leaders and experts on a panel discussion at the 30th Annual BIO-Europe conference, held in Stockholm, Sweden, from 4th-6th November 2024.

Locations